07:30 EST AbbVie to acquire ImmunoGen for $31.26 per share in cash
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV:
- AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker
- M & A News: AbbVie’s (NYSE:ABBV) $10.1B Gamble on ImmunoGen Sends Shares Soaring
- AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
- AbbVie (NYSE:ABBV) Sees Positive Results in Lung Cancer Drug Trial
- AbbVie announces results from single-arm Phase 2 LUMINOSITY trial